SYNTHON HISPANIA SL
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Medicinal Chemicals and Botanical Products), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about SYNTHON HISPANIA SL
Live alerts from global media, monitored by Business Radar
2024-12-17 (investorsinhealthcare.com)
Netherlands: BC Partners sells stake in Synthon to Goldman Sachs Alternatives for reported US$2bn valuation - Investors in Healthcare
BC Partners sells stake in Synthon to Goldman Sachs Alternatives
Read more
2008-09-08 (fiercebiotech.com)
Perrigo Company (PRGO) Acquires Exclusive Sales
Perrigo Company( PRGO) Acquires Exclusive Sales and Distribution Rights to Allergy Drug Levocetirizine from Synthon Pharmaceuticals ALLEGAN, Mich., Sept.8 /PRNewswire-FirstCall/ -- Perrigo Company| Perrigo Company( PRGO) Acquires Exclusive Sales and Distribution Rights to Allergy Drug Levocetirizine
Read more